This article is more than 5 years old. Information may no longer be current.
Antibody prevents retinal neovascularization in animal model
Click Here to Manage Email Alerts
GAINESVILLE, Fla. — An antibody that targets retinal neovascularization is showing promising results in animal studies, according to a press release from the product developer.
RegenMed is developing a compound that targets SDF-1, a cytokine that allows cells to “talk” to one another, according to the release. The company’s treatment is the “first that we know of that targets SDF-1, which may be a better target than the target of other potential treatments coming to market,” said Edward Scott, MD, in the release. Dr. Scott presented results of nonhuman primate studies of the antibody at an angiogenesis meeting sponsored by Bascom Palmer Eye Institute.
According to RegenMed, numerous tissues in the body can turn on the expression of SDF-1 in response to an injury.
“SDF-1 recruits many blood cell types to areas of the body where it is expressed,” the release said. RegenMed has developed an antibody injection that blocks SDF-1 activity before it allows vessels to grow, “suggesting this would make a good preventative therapy,” the release said.
The company is now preparing the antibody for human trials.